In This Section

Surmounting the Insurmountable: Obstacles in Drug Discovery and Development - Real World Case Studies

Monday April 23, 2018

9:30 am - 12:00 pm Eastern Time (ET)

Room 16A


Chair :

Kan He

Paul Hollenberg
University of Michigan

During the drug discovery and development process in the real world, expert scientists frequently encounter an unexpected obstacle that seems insurmountable. Serious issues with efficacy, toxicity, and pharmacokinetics may unexpectedly threaten the successful development of the whole project. How do experienced scientists deal with such issues? Critical thinking and problem solving are essential for success. This session features recognized experts in drug discovery and development and their fascinating and challenging stories. What went fatally wrong with a particular drug? How was the problem solved?


Margaret Bradbury - Prana Biotech

Challenges and Solutions in the Approval of Austedo, the First Deuterium-Substituted Small Molecule

Francis Lee - Angex Pharmaceutical Inc.

Discovery and Development Challenges of Dasatinib for the Treatment of Chronic Myelogenous Leukemia and Beyond

Sandeep Dutta - Amgen

Modeling and Simulation that Resulted in the Progression of Evolucumab

Francis Wolenski - Takeda Pharmaceuticals International Co.

Fasiglifam (TAK-875) Alters Bile Acid Homeostasis in Rats and Dogs: A Potential Cause of Drug Induced Liver Injury

Paul Hollenberg - University of Michigan